Hey @Albert Lancellotti it’s not about “which is best,” but what pathway you’re targeting. - Sermorelin (GHRH analog) → works via your own GH axis. Research shows it can increase GH/IGF-1 even in older adults, but effects are modest and depend on pituitary responsiveness - Tirzepatide (GLP-1/GIP pathway) → acts on metabolic signaling, not GH. Different mechanism entirely, mainly studied for glucose and weight regulation - “Wolverine” blends → mostly unstandardized combos; limited controlled data and higher variability in quality/consistency. Key context: GH output drops ~14% per decade after 30, so GH-based peptides can still respond, but the magnitude is smaller and slower with age Read these as a reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/ https://time.com/7380810/anti-aging-peptide-shots-social-media/ https://pmc.ncbi.nlm.nih.gov/articles/PMC3940699/